Patients with any TP53 abnormality, including del(17p), have shorter progression-free survival (PFS) and overall survival (OS) and are less responsive to traditional chemoimmunotherapy used in CLL [24,25]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.